रेमिफेंटानिल और वेक्यूरोनियम का इंटरैक्शन

In the case of life-threatening muscle rigidity, a rapid onset neuromuscular blocker or naloxone may be administered.

Muscle rigidity occurring during the induction of anesthesia should be treated by the administration of a neuromuscular blocking agent and the concurrent induction medications and can be treated by decreasing the rate or discontinuing the infusion of ULTIVA or by administering a neuromuscular blocking agent.

The neuromuscular blocking agents used should be compatible with the patient's cardiovascular status.